Correlation Between Virpax Pharmaceuticals and Acurx Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and Acurx Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and Acurx Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virpax Pharmaceuticals and Acurx Pharmaceuticals LLC, you can compare the effects of market volatilities on Virpax Pharmaceuticals and Acurx Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of Acurx Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and Acurx Pharmaceuticals.

Diversification Opportunities for Virpax Pharmaceuticals and Acurx Pharmaceuticals

0.72
  Correlation Coefficient

Poor diversification

The 3 months correlation between Virpax and Acurx is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and Acurx Pharmaceuticals LLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acurx Pharmaceuticals LLC and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with Acurx Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acurx Pharmaceuticals LLC has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and Acurx Pharmaceuticals go up and down completely randomly.

Pair Corralation between Virpax Pharmaceuticals and Acurx Pharmaceuticals

Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to generate 1.16 times more return on investment than Acurx Pharmaceuticals. However, Virpax Pharmaceuticals is 1.16 times more volatile than Acurx Pharmaceuticals LLC. It trades about -0.18 of its potential returns per unit of risk. Acurx Pharmaceuticals LLC is currently generating about -0.34 per unit of risk. If you would invest  65.00  in Virpax Pharmaceuticals on September 15, 2024 and sell it today you would lose (25.00) from holding Virpax Pharmaceuticals or give up 38.46% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Virpax Pharmaceuticals  vs.  Acurx Pharmaceuticals LLC

 Performance 
       Timeline  
Virpax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Acurx Pharmaceuticals LLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Acurx Pharmaceuticals LLC has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Virpax Pharmaceuticals and Acurx Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Virpax Pharmaceuticals and Acurx Pharmaceuticals

The main advantage of trading using opposite Virpax Pharmaceuticals and Acurx Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, Acurx Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will offset losses from the drop in Acurx Pharmaceuticals' long position.
The idea behind Virpax Pharmaceuticals and Acurx Pharmaceuticals LLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bonds Directory
Find actively traded corporate debentures issued by US companies